Edition:
India

Beigene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

273.96USD
18 Sep 2020
Change (% chg)

$11.34 (+4.32%)
Prev Close
$262.62
Open
$267.62
Day's High
$275.34
Day's Low
$262.90
Volume
236,744
Avg. Vol
111,194
52-wk High
$275.34
52-wk Low
$115.00

Select another date:

Thu, Aug 27 2020

China's BeiGene to start human testing of COVID-19 antibody treatment in September

China-based drugmaker BeiGene Ltd said on Thursday that an early-stage human study to test its COVID-19 antibody treatment will begin in September.

China's BeiGene to start human testing of COVID-19 antibody treatment in September

Aug 27 China-based drugmaker BeiGene Ltd said on Thursday that an early-stage human study to test its COVID-19 antibody treatment will begin in September.

BRIEF-Beigene Says Began Commercializing Xgeva (Denosumab) In China

* ON JUNE 30, CO BEGAN COMMERCIALIZING XGEVA (DENOSUMAB) IN CHINA FOR TREATMENT OF GIANT CELL TUMOR OF BONE Source text https://bit.ly/2ZpQivq Further company coverage:

BRIEF-BeiGene Announces Acceptance Of Supplemental New Drug Application For Tislelizumab

* BEIGENE ANNOUNCES ACCEPTANCE OF A SUPPLEMENTAL NEW DRUG APPLICATION FOR TISLELIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE HEPATOCELLULAR CARCINOMA IN CHINA Source text for Eikon: Further company coverage:

BRIEF-Beigene And Springworks Announce Presentation Of Preclinical Data From Solid Tumors Treatment

* BEIGENE AND SPRINGWORKS ANNOUNCE PRESENTATION OF PRECLINICAL DATA COMBINING RAF DIMER INHIBITOR LIFIRAFENIB WITH MEK INHIBITOR MIRDAMETINIB AND PROVIDE UPDATE ON ONGOING PHASE 1B/2 CLINICAL TRIAL

BRIEF-BeiGene Announces European Medicines Agency Acceptance Of Marketing Authorization Application For BRUKINSA

* BEIGENE ANNOUNCES EUROPEAN MEDICINES AGENCY ACCEPTANCE OF ITS MARKETING AUTHORIZATION APPLICATION FOR BRUKINSA® (ZANUBRUTINIB) FOR THE TREATMENT OF PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA Source text for Eikon: Further company coverage:

BRIEF-Beigene Reports Approval Of Brukinsa In China For Small Lymphocytic Lymphoma

* BEIGENE ANNOUNCES THE APPROVAL OF BRUKINSA™ (ZANUBRUTINIB) IN CHINA FOR PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA AND RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

BRIEF-Beigene Says Aspen Trial Did Not Achieve Statistical Significance On Its Primary Endpoint

* ASPEN TRIAL DID NOT ACHIEVE STATISTICAL SIGNIFICANCE ON ITS PRIMARY ENDPOINT Source text for Eikon: Further company coverage:

BRIEF-Beigene Presents Phase 3 Data On Tislelizumab Combined With Chemotherapy For The Treatment Of Patients With Advanced Squamous Non-Small Cell Lung Cancer

* BEIGENE PRESENTS PHASE 3 DATA ON TISLELIZUMAB COMBINED WITH CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER AT THE 2020 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) VIRTUAL SCIENTIFIC PROGRAM

BRIEF-Beigene Presents Updated Results From Phase 3 Trial Of Zanubrutinib vs Ibrutinib In Patients With Waldenström’S Macroglobulinemia

* BEIGENE PRESENTS UPDATED HEAD TO HEAD RESULTS FROM PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS. IBRUTINIB IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA AT THE 2020 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) VIRTUAL SCIENTIFIC PROGRAM Source text for Eikon: Further company coverage:

Select another date: